Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Rheumatology

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 15124262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis.

  2002cited by this paper
• Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis.

  2002cited by this paper
• Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.

  2002cited by this paper
• Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures

  2002cited by this paper
• Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.

  2002cited by this paper
• Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

  2001cited by this paper
• The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis.

  2001cited by this paper
• Evaluation of the role of RANK and OPG genes in Paget's disease of bone.

  2001cited by this paper
• Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

  2001cited by this paper
• Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

  2001cited by this paper
• Osteoprotegerin: a link between osteoporosis and arterial calcification?

  2001cited by this paper
• Rheumatoid arthritis synovial macrophage–osteoclast differentiation is osteoprotegerin ligand‐dependent

  2000cited by this paper
• The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

  2000cited by this paper
• Pathogenesis of bone erosions in rheumatoid arthritis

  2000cited by this paper
• Osteoprotegerin and its Ligand: A New Paradigm for Regulation of Osteoclastogenesis and Bone Resorption

  2000cited by this paper
• Bone mineral status in juvenile rheumatoid arthritis.

  2000cited by this paper
• The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption

  2000cited by this paper
• Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.

  2000cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

  1999cited by this paper
• Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis

  1999cited by this paper
• Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

  1999cited by this paper
• Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis.

  1998cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Growth retardation and bone loss as determinants of axial osteopenia in juvenile chronic arthritis.

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis.

  1996cited by this paper
• Genetic determinants of bone mass in adults. A twin study.

  1987cited by this paper

• The assessment and management of bone health in pediatric-onset rheumatological diseases from early age to adulthood: A critical overview.

  2025cites this paper
• Effects of a Functional Ice Cream Enriched with Milk Proteins on Bone Metabolism: A Feasibility Clinical Study and In Vitro Investigation

  2023cites this paper
• Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms

  2023cites this paper
• Bone Health in Children with Rheumatic Disorders: Focus on Molecular Mechanisms, Diagnosis, and Management

  2022cites this paper
• Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study

  2021cites this paper
• The influence of vitamin D administration on the clinical presentation, body mass index, and osteoprotegerin (OPG) level in a sample of Egyptian children with familial Mediterranean fever

  2021cites this paper
• Osteoporosis in Systemic Autoinflammatory Diseases: A Case-Control Study

  2019cites this paper
• Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts

  2018cites this paper
• Is it possible to predict a risk of osteoporosis in patients with juvenile idiopathic arthritis? A study of serum levels of bone turnover markers.

  2018cites this paper
• Chapter 53 – The Impact of Rheumatic Diseases and Their Treatment on Bone Strength Development in Childhood

  2016cites this paper
• Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.

  2015cites this paper
• Wybrane czynniki proapoptotyczne i antyapoptotyczne w młodzieńczym idiopatycznym zapaleniu stawów

  2014cites this paper
• Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis

  2014cites this paper
• The role of the serum RANKL/OPG ratio in the healing of intertrochanteric fractures in elderly patients.

  2013cites this paper
• Osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in children with inflammatory bowel disease Stężenie osteoprotegeryny i liganda receptora aktywującego czynnik jądrowy κB w przebiegu nieswoistych zapaleń jelit u dzieci

  2013cites this paper
• Czynniki prozapalne, proapoptotyczne i antyapoptotyczne w patogenezie autoimmunologicznej choroby tarczycy

  2013cites this paper
• Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis

  2012cites this paper
• Osteoprotegerin, Insulin Like Growth Factor-1 and Bone Changes in Prepubertal Males With Type 1 Diabetes Mellitus

  2012cites this paper
• Emerging drugs to treat juvenile idiopathic arthritis

  2011cites this paper
• Protein deficiency and nematode infection during pregnancy and lactation reduce maternal bone mineralization and neonatal linear growth in mice.

  2010cites this paper
• Rola RANKL, osteoprotegeryny i TRAIL w monitorowaniu zaburzeń kostnych w młodzieńczym idiopatycznym zapaleniu stawów

  2010cites this paper
• Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study

  2010influential citation
• Changes in serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, IL-6 and TNF-α in patients with a concomitant head injury and fracture

  2009cites this paper
• Oligoarticular and polyarticular JIA: epidemiology and pathogenesis

  2009cites this paper
• Increased serum osteoprotegerin levels associated with decreased bone mineral density in familial Mediterranean fever.

  2009cites this paper
• Association between osteoporosis and rheumatoid arthritis in women: a cross-sectional study

  2009cites this paper
• Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis

  2009cites this paper
• Evaluation of bone mineral density and bone turnover markers in Egyptian children with juvenile rheumatoid arthritis

  2009influential citation
• Elevated serum receptor activator of NFκB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis

  2008influential citation
• Percent true calcium absorption, mineral metabolism, and bone mass in children with arthritis: effect of supplementation with vitamin D3 and calcium.

  2008cites this paper
• Interleukin-17–producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers

  2008cites this paper
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

  2008cites this paper
• Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.

  2008cites this paper
• Osteoprotegerin/RANKL system imbalance in active polyarticular‐onset juvenile idiopathic arthritis: a bone damage biomarker?

  2008cites this paper
• Avaliação do sistema osteoprotegerina e RANKL em pacientes com artrite idiopática juvenil de início poliarticular

  2008cites this paper
• RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.

  2007cites this paper
• Short digits...what's up?

  2007cites this paper
• Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover

  2007cites this paper
• Can Exercise Influence Low Bone Mineral Density in Children with Juvenile Rheumatoid Arthritis?

  2007cites this paper
• Osteoprotegerin and RANKL Serum Levels and Their Relationship with Serum Ghrelin in Children with Chronic Renal Failure and on Dialysis

  2007cites this paper
• The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis.

  2007cites this paper
• Plasma levels of receptor activator of nuclear factor‐κB ligand and osteoprotegerin in patients with neuroblastoma

  2006cites this paper
• Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status.

  2005cites this paper
• Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein.

  2005cites this paper
• Efficacy of 1-year treatment of risedronian in postmenopausal women in conection with polymorphism of OPG gene

  2005cites this paper
• Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.

  2005cites this paper
• Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.

  2005cites this paper
• Bone health in pediatric rheumatic disease

  2005cites this paper
• The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.

  2004cites this paper